What is not here
Brands from outside the US, the EU and the EEA. A brand authorised only in, say, Switzerland, Canada or Australia is in none of the three lists and may be missing. Reverse lookups for EU/EEA national brands. Typing a generic (paracetamol) lists the US brands and the EU centrally authorised brands, not the tens of thousands of national brands in the Article 57 list: that list is searched by brand name, one first letter at a time. The abroad lookup turns it round: type a substance or brand, pick a country, and see the brand names there with exactly the same active substance(s). Products named after their own substance. In the Article 57 list a product called Paracetamol Teva or Diklofenak Apofri (a national spelling of diclofenac) is a generic sold under its substance's name, not a brand, and is not indexed. Names written in Greek or Cyrillic letters (some Bulgarian, Greek and Cypriot entries) cannot be typed as a Latin name and are left out. Veterinary medicines and medicines EMA never authorised (refused, or applications withdrawn before a decision) are left out of the EU list. Most over-the-counter monograph products and all supplements. Drugs@FDA lists medicines approved through an application, so many shop-shelf products sold under FDA's over-the-counter monographs, and every dietary supplement, are absent. Vaccines and blood products licensed by FDA's biologics centre are mostly not in Drugs@FDA either. Old names may be missing. Misspelled names are matched only as the lists spell them: when nothing starts with what you typed, the lookup offers up to five listed names spelled closest to it (for example lipiter offers LIPITOR), each marked with the list it comes from. A suggestion is only a spelling candidate; many medicine names look or sound alike, so check the pack or prescription. When a name is not found, the lookup says so plainly; ask a pharmacist, who can read the generic name off the pack or label. Strengths and forms are left out on purpose: the data file keeps name fields only.
Source and how the list was built
FDA publishes Drugs@FDA as a set of data files, and its openFDA project republishes the same records as one drugsfda bulk file. On 2026-09-23 the FDA data-files download refused scripted requests, so this list was built from the openFDA file of the same day (checked 2026-09-23). Both are US Government works in the public domain.
From each of the 51,788 product records a script (tools/build-brands.cjs) keeps only the drug name, the active ingredient names and the marketing status, splits combination products into one name per ingredient, and drops strength, form and route. A drug name counts as a brand only if it still differs from its own ingredient names once connecting words, numbers and packaging words are set aside, so the 37,197 records sold under their ingredient name (ATORVASTATIN CALCIUM from a generic maker) are not called brands. Also left out: 1,417 records with only a tentative approval, and 565 records (401 distinct names) whose name carries a strength or form, such as intravenous fluids named with a percentage. What remains is 7,714 rows covering 5,883 US brand names and 2,535 plain generic names. The whole list is one file, brands.json (about 470 KB), which this page loads once and searches in your browser.
EU names. The European Medicines Agency publishes its list of medicines as open data on its download medicine data page. The EU list here was built from the JSON edition, downloaded on 2026-09-24 (checked 2026-09-24; EMA's export time 2026-09-24 06:07 UTC). Of its 2,746 rows a second script (tools/build-brands-eu.cjs) drops the 395 veterinary medicines and 364 human medicines that were never authorised (268 applications withdrawn, 64 refused, 28 opinions not yet decided, 2 under re-examination, 2 withdrawn from rolling review). From each remaining row it reads the medicine's name, its INN (split into one name per ingredient), EMA's status word and the address of its EMA page; the therapeutic-area and indication text, codes, dates and company fields in EMA's file are discarded as the file is read and appear nowhere on this site. No row tripped the site's names-only check. What remains is 1,987 rows covering 1,979 EU brand names, in one file, brands-eu.json (about 180 KB), loaded together with the US list.
EU and EEA countries. Under Article 57(2) of Regulation (EC) No 726/2004, every marketing-authorisation holder reports each medicine it holds in the EU or EEA to EMA, whether it was authorised centrally or by one country's own agency. EMA publishes the resulting list as the Article 57 product data spreadsheet, one row per product per country, on its public-data page. The copy used here was downloaded on 2026-09-25 and has 164,314 rows. A third script (tools/build-brands-eea.cjs) reads only three columns (product name, active substance, authorisation country); the company, route, pharmacovigilance contact e-mail, telephone and file-location columns are skipped as the file is read and appear nowhere on this site. It cuts each product name before its first strength number, removes salt words from the substances, and leaves out 66,925 rows named after their own substance (and 981 more rows whose name is a generic in another form: an INN, a national spelling of one such as Loxapin or Alendronato, an official or FDA name such as Nitroglycerin or Alendronic Acid, or a name that is its own substance on some other row, so a typed generic never comes back as a brand), 3,829 rows whose name is in Greek or Cyrillic letters and 214 rows that tripped the site's names-only check. When one name covers different substances in different rows, the substances most rows give are kept (4,401 rows set aside that way), so two products are never merged into an invented combination. What remains is 42,952 brand names, split into one file per first letter (up to about 320 KB each). The page fetches only the file for the letter you typed.
Credit. EU names: Source: European Medicines Agency (EMA). EU and EEA names: Source: European Medicines Agency (EMA), Article 57 product data, downloaded 2026-09-25. EMA's legal notice (checked 2026-09-25) allows its information to be reproduced for non-commercial and commercial purposes provided EMA is always acknowledged as the source. The EMA medicines list covers centrally authorised medicines only; the Article 57 list covers medicines authorised in any EU or EEA country, and is a list of names reported by companies, not a record of what is on a pharmacy shelf.